Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

25.55 USD -1.20 (-4.49%)
Official Closing Price Updated: 7:58 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Esperion Theraptc

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Kaskela Law LLC: Shareholder Class Action Filed Against Esperion Therapeutics, Inc. - ESPR
Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Esperion Therapeutics, Inc. (NASDAQ:ESPR) (“Esperion” or the “Company”) on behalf of purchasers of the Company’s... 
From GlobeNewswire News Releases
Pomerantz Law Firm Announces the Filing of a Class Action against Esperion Therapeutics, Inc. and Certain Officers – ESPR
Pomerantz LLP announces that a class action lawsuit has been filed against Esperion Therapeutics, Inc. (“Esperion” or the “Company”) (NASDAQ:ESPR) and certain of its officers. The class action, filed... 
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Esperion Therapeutics, Inc. - ESPR
From ACCESSWIRE
Esperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care Conference
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Esperion Therapeutics, Inc. (ESPR)
From ACCESSWIRE
Important Stock Score Report Updates for Esperion Therapeutics, Integrated Media Technology, Mastercard, Molson Coors, and Wayfair
InvestorsObserver issues critical PriceWatch Alerts for ESPR, IMTE, MA, TAP, and W. 
From PR Newswire
Stock Review for Biotech's Investors -- BioTime, Eleven Biotherapeutics, Endocyte, and Esperion Therapeutics
From PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Esperion Therapeutics, Inc. - ESPR
Pomerantz LLP is investigating claims on behalf of investors of Esperion Therapeutics, Inc. ("Esperion" or the "Company") (NASDAQ: ESPR). Such investors are advised to contact Robert S. Willoughby at... 
From PR Newswire
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Esperion Therapeutics, Inc. (ESPR)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Esperion Therapeutics, Inc. ("Esperion" or the "Company") (NASDAQ: ESPR). Such... 
From PR Newswire
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Long-Term Safety Study of Bempedoic Acid
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
Investor Expectations to Drive Momentum within Esperion Therapeutics, Celestica, Sapiens International Corporation N.V, Royal Bank Of Canada, CSS Industries, and SSR Mining — Discovering Underlying Fa
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Esperion Therapeutics, Inc.... 
From GlobeNewswire News Releases
Pre-Market Technical Scan on Biotech Equities -- Eleven Biotherapeutics, Endocyte, Esperion Therapeutics, and Exelixis
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on EBIO, ECYT, ESPR, and EXEL which can be accessed for free by signing up to... 
From PR Newswire
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with Hypercholesterolemia
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
New Research Coverage Highlights Star Bulk Carriers, IPG Photonics, Mellanox Technologies, Hollysys Automation Technologies, Esperion Therapeutics, and Yirendai — Consolidated Revenues, Company Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Star Bulk Carriers Corp.... 
From GlobeNewswire News Releases
Esperion to Participate in Fireside Chat at March 2018 Investor Conferences
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2017 Financial Results
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with... 
From GlobeNewswire News Releases
How CEO's of Biotech are Incentivized and What This Means for Investors
From PR Newswire
Esperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare Conference
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment... 
From GlobeNewswire News Releases
Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment... 
From GlobeNewswire News Releases
Biotech's Flying Under The Radar
MicroCapSpeculators.com News Commentary 
From PR Newswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment... 
From GlobeNewswire News Releases
Esperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare Conference
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment... 
From GlobeNewswire News Releases
Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment... 
From GlobeNewswire News Releases
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment... 
From GlobeNewswire News Releases
Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment... 
From GlobeNewswire News Releases
Biotech Stocks on Investors' Radar -- Curis, Egalet, Esperion Therapeutics, and GlycoMimetics
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.